BioNTech
VC Fund
Mainz, Germany
BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries BioNTech invests in
Stages BioNTech invests in
Countries BioNTech invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Post-IPO Equity
- $21M–$29M
Investment Focus
Industry
- Biotechnology 4 (67%)
- Health Care 3 (50%)
- Medical 2 (33%)
- Therapeutics 2 (33%)
- Pharmaceutical 2 (33%)
Stage
- Post-IPO Equity 2 (33%)
- Pre-Seed 1 (17%)
- Series B 1 (17%)
- Funding Round 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- United Kingdom 3 (50%)
- Germany 2 (33%)
- Poland 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Annemarie Hanekamp
Chief Commercial Officer
|
Chief Commercial Officer | Total investments: 0 | Find email | |
Arvind m. Hundal Ph.d.
SVP Business Development
|
SVP Business Development | Total investments: 0 | Find email | |
Christoph Huber
Cofounder & deputy chair supervisory board
|
Cofounder & deputy chair supervisory board | Total investments: 0 | Find email | |
Christoph Kröner
Director DNA Process Development & Cap Technology
|
Director DNA Process Development & Cap Technology | Total investments: 0 | Find email | |
Jesse Dong
Vice President, Peptide Chemistry
|
Vice President, Peptide Chemistry | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sortera Bio
|
Sortera Bio operates as a biotechnology company. Sortera is committed to providing revolutionary solutions in biologics discovery. | $10.2M / Pre-Seed / Jun 05, 2025 | |
Crescendo Biologics
|
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $32M / Jul 24, 2023 | |
Greenforce
|
Greenforce creates and sells plant-based foods that are good for both people and the environment. Its products are 100% vegan, made with high-quality raw materials sourced from reputable suppliers, and the entire value chain is transparent. It aims to secure the protein supply for future generations, who cannot be fed animal proteins. | $13.7M / Venture - Series Unknown / Dec 07, 2022 | |
Ryvu
|
Ryvu is a biopharmaceutical company developing small-molecule therapies that address the clinical limitations of current treatments in oncology. | $20.8M / Post-IPO Equity / Nov 30, 2022 | |
MediGene
|
MediGene is a company that specializes in biotechnology specifically in the treatment of cancer. | $29.4M / Post-IPO Equity / Feb 21, 2022 | |
InstaDeep
|
InstaDeep is an EMEA leader in decision-making AI products for the Enterprise, with headquarters in London, and offices in Paris, Tunis, Lagos, Dubai and Cape Town. With expertise in both machine intelligence research and concrete business deployments, the Company provides a competitive advantage to its partners in an AI-first world. Leveraging itsextensive knowhow in GPU-accelerated computing, deep learning and reinforcement learning, InstaDeep has built products, such as its novel DeepChain™ platform, that tackle the most complex challenges across a range of industries. InstaDeep has also developed collaborations with global leaders in the Artificial Intelligence ecosystem, such as Google DeepMind, NVIDIA and Intel. The Company is part of Intel’s AI Builders program and was named an Elite Preferred Deep Learning Partner by NVIDIA | $100M / Series B / Jan 25, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does BioNTech invest in?
BioNTech invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BioNTech's check size?
BioNTech typically joins rounds of $21M–$29M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BioNTech participates in.
How do I contact BioNTech?
Public channels for BioNTech include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BioNTech?
The team at BioNTech includes Annemarie Hanekamp (Chief Commercial Officer), Arvind m. Hundal Ph.d. (SVP Business Development) and Christoph Huber (Cofounder & deputy chair supervisory board), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
